Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Mark Mascarenhas

Clinical Cardiac Electrophysiology Eatontown, NJ Medical Doctor

NPI 1841477817 CMS profile 265594

11 Meridian Rd, Ste 104, Eatontown, NJ 07724

Open in the dashboard

General payments

$17,476

283 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$306,519 paid to institutions, not to them · program years 2019–2024

Through program year 2025, Mark Mascarenhas of Eatontown, NJ is reported in the CMS Open Payments database as having received $17,476 across 283 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $306,519 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 48th percentile of Clinical Cardiac Electrophysiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,451 61
2024 General $657 34
2023 General $2,945 47
2022 General $1,029 49
2021 General $909 31
2020 General $439 21
2019 General $10,047 40

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Mark Mascarenhas
  • Clinical Cardiac Electrophysiology median
  • Middle half of Clinical Cardiac Electrophysiology
  • National median

In program year 2025, general payments to Mark Mascarenhas were reported at $1,451. Among 3,064 Clinical Cardiac Electrophysiology profiles paid that year, the median was $2,462 and the middle half received between $733 and $7,710.

Show as a table
Year Mark Mascarenhas Clinical Cardiac Electrophysiology median Middle half National median
2019 $10,047 $2,361 $585–$8,260 $163
2020 $439 $993 $247–$4,351 $114
2021 $909 $1,185 $326–$4,739 $132
2022 $1,029 $2,073 $554–$6,789 $149
2023 $2,945 $2,568 $759–$8,159 $160
2024 $657 $2,557 $703–$7,403 $164
2025 $1,451 $2,462 $733–$7,710 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Boston Scientific Corporation $10,996 105 payments
  2. Medtronic, Inc. $2,751 26 payments
  3. Abbott Laboratories $1,297 52 payments
  4. Biotronik Inc. $369 3 payments
  5. Novartis Pharmaceuticals Corporation $283 17 payments
  6. Impulse Dynamics (USA) Inc. $263 10 payments
  7. Amgen Inc. $206 12 payments
  8. Janssen Pharmaceuticals, Inc $146 10 payments
  9. E.R. Squibb & Sons, L.L.C. $144 7 payments
  10. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $135 7 payments
  11. Other $885 34 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $8,000 2 payments
  2. Food and Beverage $6,297 262 payments
  3. Travel and Lodging $2,867 18 payments
  4. Consulting Fee $313 1 payment
Products named General payments · program years 2019–2025
  1. WATCHMAN $9,007 15 payments
  2. AVEIR Structural Heart $615 24 payments
  3. RESONATE Tachy $517 17 payments
  4. Siello $313 1 payment
  5. RESONATE Pain Management $261 5 payments
  6. AVEIR Cardiac Rhythm Management $223 16 payments
  7. ENTRESTO $181 11 payments
  8. AFFERA MAPPING SYSTEM $177 3 payments
  9. RESONATE Resonate $166 4 payments
  10. Optimizer Smart System $164 7 payments
  11. Other $3,342 162 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 41 drugs

Part D claims

2,408

Median for Clinical Cardiac Electrophysiology: 1,090

Drug cost

$1,183,743

Median for Clinical Cardiac Electrophysiology: $354,841

Branded share of claims

36.5%

Median for Clinical Cardiac Electrophysiology: 38.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 453 $495,930
Vyndamax Tafamidis Brand 14 $354,037
Xarelto Rivaroxaban Brand 71 $97,410
Entresto Sacubitril/Valsartan Brand 36 $67,879
Multaq Dronedarone Hcl Brand 25 $40,804
Farxiga Dapagliflozin Propanediol Brand 25 $32,363
Repatha Sureclick Evolocumab Brand 20 $19,718
Dofetilide Generic 97 $17,705
Edarbi Azilsartan Medoxomil Brand 30 $13,386
Propafenone Hcl Er Propafenone Hcl Brand 32 $9,306

The 10 drugs with the highest cost, of 41 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,573 Part D prescribers listed as Clinical Cardiac Electrophysiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 76 billing codes

Paid by Medicare

$642,450

Medicare's payments for the services billed

Medicare patients

2,622

Average age 78

Services billed

7,606

1,166 women, 1,456 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Atrial fibrillation 64%
Ischemic heart disease 61%
Arthritis 54%
Heart failure 46%
Diabetes 38%
Chronic kidney disease 35%
COPD 24%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 7 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ELIQUIS
  • PFIZER INC. $22
  • E.R. Squibb & Sons, L.L.C. $14
$37 453 —
Repatha
  • Amgen Inc. $34
$34 20 —
AMVUTTRA
  • Alnylam Pharmaceuticals Inc. $34
$34 — —
LEQVIO
  • Novartis Pharmaceuticals Corporation $28
$28 — —
VYNDAQEL
  • PFIZER INC. $15
$15 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 7 in the dashboard with a free account

Records

283 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Clinical Cardiac Electrophysiology in New Jersey

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record